
11 Jun 2019
Melvyn’s story
In 2012 Melvyn, a bone marrow transplant patient, suffering from an aggressive form of graft-versus-host-disease was given pioneering, life-saving treatment, Mesenchymal Stem Cell Therapy, at The Catherine Lewis Centre.
“I was first diagnosed with leukaemia in July 1998 after complaining of fatigue to my local GP,” says Melvyn.
“I didn’t know what the disease was at the time but my wife Pauline took the news very badly as she understood what the outcome could be.
“I wanted to see my children graduate – my daughter was 13 and my son 15 – so I was determined to fight it and stay positive. It was a huge shock for my family.”
Melvyn successfully underwent a stem cell transplant just 10 weeks later, and although he responded well initially he started to experience a serious complication called graft-versus-host-disease (GvHD), where the newly transplanted cells attack the recipient’s body.
“I remember reaching out to turn the bedside lamp off and noticing for the first time hard lumps on my arms. By the time I went to clinic, it had spread all over my body from my neck to my ankles and my skin had become so thick that I found it hard to move.
“I saw the rheumatologist and started a new steroid drug regime, it worked well for around two years, but the risk of infection and relapse were so high that I stopped taking them.
“After a couple of years GvHD deteriorated; but thankfully, because of research funded by Leukaemia UK, I was given the opportunity to trial a new treatment called Mesenchymal Stem Cell Therapy, which has significantly improved my life.”
Professor Francesco Dazzi
“Leukaemia UK has enabled us to initiate this treatment and gather preliminary evidence with some extraordinary results. In Melvyn’s case, we isolated cells taken from his daughter, prepared them here at The Catherine Lewis Centre and, when they were ready, we infused them.
“We have seen a 50% improvement in Melvyn’s condition and I am thrilled that we have been able to improve both his outlook and quality of life.”
Related posts
4 September 2022
Worrying numbers of leukaemia patients are being misdiagnosed or waiting too long for a blood test, say leading UK leukaemia charities
Patients in the UK face “the luck of the draw” when presenting with leukaemia symptoms. GPs are often left without adequate support to provide blood tests or process the results…
22 May 2023
Can the unique differences between stem cells tell us how well CML treatment will work?
What if we could predict how chronic myeloid leukaemia (CML) patients will respond to treatment? Could the unique signatures of CML stem cells hold the key to personalising treatment for…
28 November 2022
Leukaemia UK John Goldman Fellow awarded Professorship
Talented blood cancer researcher, Vignir Helgason, was awarded a Leukaemia UK John Goldman Fellowship in 2015, for his research into chronic myeloid leukaemia (CML). Since then, his research career has…
30 January 2024
Leukaemia UK bolsters research and advocacy team, in support of ambitious strategy to accelerate progress in the diagnosis, treatment, and care of leukaemia
Leukaemia UK is pleased to announce Dr Simon Ridley as the new Director of Research and Advocacy and Dr Georgia Papacleovoulou as the organisation’s first ever Head of Policy and…